Gritstone bio Dirección

Dirección controles de criterios 2/4

El CEO de Gritstone bio's es Andrew Allen , nombrado en Aug 2015, tiene una permanencia de 8.67 años. compensación anual total es $2.68M, compuesta por 23.2% salario y 76.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.47% de las acciones de la empresa, por valor de $1.17M. La antigüedad media del equipo directivo y de la junta directiva es de 3.1 años y 6.3 años, respectivamente.

Información clave

Andrew Allen

Chief Executive Officer (CEO)

US$3.4m

Compensación total

Porcentaje del salario del CEO	18.8%
Permanencia del CEO	8.8yrs
Participación del CEO	1.5%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	6.4yrs

Actualizaciones recientes de la dirección

Recent updates

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Apr 07

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14

Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation

May 26

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andrew Allen en comparación con los beneficios de Gritstone bio?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$145m
Dec 31 2023	US$3m	US$646k	-US$138m
Sep 30 2023	n/a	n/a	-US$139m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$620k	-US$120m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$116m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$589k	-US$75m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$2m	US$569k	-US$105m
Sep 30 2020	n/a	n/a	-US$106m
Jun 30 2020	n/a	n/a	-US$107m
Mar 31 2020	n/a	n/a	-US$103m
Dec 31 2019	US$2m	US$533k	-US$94m
Sep 30 2019	n/a	n/a	-US$84m
Jun 30 2019	n/a	n/a	-US$75m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$475k	-US$65m
Sep 30 2018	n/a	n/a	-US$65m
Jun 30 2018	n/a	n/a	-US$56m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$592k	US$436k	-US$41m

Compensación vs. Mercado: La compensación total de Andrew($USD2.68M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Andrew ha aumentado mientras la empresa no es rentable.

CEO

Andrew Allen (57 yo)

8.8yrs

Permanencia

US$3,444,071

Compensación

Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph D., serves as Independent Director at Verge Analytics, Inc. since September 2021. He has also held clinical development leadership positions at Chiron Corpo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Allen	Co-Founder	8.8yrs	US$3.44m	1.46% $ 1.5m
Erin Jones	Executive VP & COO	3.2yrs	US$1.52m	0.050% $ 51.6k
Karin Jooss	Executive VP and Head of Research & Development	3.2yrs	US$1.58m	0.35% $ 367.1k
Vassiliki Economides	Executive VP & CFO	2.9yrs	sin datos	0.033% $ 34.0k
James Cho	Chief Accounting Officer	3.3yrs	sin datos	0.058% $ 60.1k
George MacDougall	Director of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Stacy Proctor	Executive VP & Chief People Officer	2.8yrs	sin datos	sin datos
Matthew Hawryluk	Executive VP & Chief Business Officer	8.5yrs	sin datos	0.072% $ 75.2k

3.2yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GRTS se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Allen	Co-Founder	8.8yrs	US$3.44m	1.46% $ 1.5m
Elaine Jones	Independent Chairman of the Board	4.7yrs	US$176.00k	0% $ 0
Steve Krognes	Independent Director	5.8yrs	US$148.50k	0% $ 0
Lawrence Corey	Independent Director	1.8yrs	US$132.50k	0% $ 0
Timothy Chan	Member of Scientific Advisory Board	6.9yrs	sin datos	sin datos
Eugene Zhukovsky	Member of Scientific Advisory Board	5.1yrs	sin datos	0% $ 0
Graham Lord	Member of Scientific Advisory Board	6.9yrs	sin datos	sin datos
Naiyer Rizvi	Independent Director & Member of Scientific Advisory Board	7.9yrs	US$140.00k	0% $ 0
James Gulley	Member of Scientific Advisory Board	6.9yrs	sin datos	sin datos
Alessandro Sette	Member of Scientific Advisory Board	6.9yrs	sin datos	sin datos
Shefali Agarwal	Independent Director	2.9yrs	US$138.50k	0% $ 0
Clare Fisher	Independent Director	2.3yrs	US$136.50k	sin datos

6.4yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de GRTS se considera experimentada (6.3 años de antigüedad promedio).

Gritstone bio Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Less than half of directors are independent

Less than half of directors are independent

High number of new directors

Recent updates

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Consensus revenue estimates decrease by 17%, EPS upgraded

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Consensus revenue estimates decrease by 37%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Price target decreased by 12% to US$8.80

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Consensus revenue estimates fall by 40%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Price target increased by 20% to US$10.34

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Price target increased by 20% to US$10.34

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Consensus revenue estimates fall by 53%

Price target decreased by 14% to US$8.60

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.75

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Price target decreased to US$10.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$10.00

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone reaches six-month high on publication of data for cancer vaccine

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Consensus revenue estimates increase by 14%

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Price target increased to US$16.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio announces $80M credit facility

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

Price target increased to US$16.00

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$14.67

Less than half of directors are independent

Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

Consensus revenue estimates fall by 57%

Full year 2021 earnings: EPS misses analyst expectations

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Gritstone: Why The Stock Fell On Positive Data

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Less than half of directors are independent

Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 Study (CORAL-BOOST) Evaluating A T Cell-Enhanced Self-Amplifying mRNA (SamRNA) Vaccine Against COVID-19

Gritstone bio, Inc Announces Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business

Gritstone Poised To Dominate mRNA Market

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.69 loss in 3Q 2020)

Price target decreased to US$20.33